VESALIUS-CV Trial (2025) Evolocumab in Patients without a Previous Myocardial Infarction or StrokeInternational, double-blind, randomized, placebo-controlled trial Objective:Among patients with atherosclerosis or diabetes but no prior MI or stroke, does long-term PCSK9 inhibition with evolocumab reduce the risk of first … Read More
evolocumab
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More